Key result
Oral edoxaban showed superior efficacy to oral placebo or subcutaneous dalteparin or enoxaparin for preventing venous thromboembolism after major orthopedic surgery.
Why the study?
Does edoxaban prevent venous thromboembolism in patients undergoing major orthopedic surgery?
Does edoxaban prevent venous thromboembolism in patients undergoing major orthopedic surgery?
Edoxaban is an effective oral factor Xa inhibitor for preventing venous thromboembolism after major orthopedic surgery, demonstrating superiority over standard therapies in clinical trials.
Edoxaban may offer convenient oral VTE prophylaxis post-orthopedic surgery; leaves open confirmation in larger diverse trials.
Fatal pulmonary thromboembolism is the most serious complication following surgery. Patients undergoing major orthopedic surgeries, including total hip replacement, total knee replacement, and hip fracture surgery, represent a group at particularly high risk of venous thromboembolism. Therefore, prophylaxis for thromboembolic events has been of great concern to surgeons. Edoxaban is a novel, orally available, and highly specific and direct factor Xa inhibitor. This new agent was approved for the prevention of venous thromboembolism in patients undergoing major orthopedic surgery, including total hip replacement, total knee replacement, and hip fracture surgery, by the Japanese Ministry of Health, Labor, and Welfare in 2011. Preclinical and Phase I clinical trials demonstrated several promising properties. Its rapid absorption and short life-time in blood are known. Edoxaban inhibits factor Xa activity directly and selectively. It also has a strong antithrombotic effect without any influence of food intake. Coagulation monitoring is not required. Edoxaban has predictable linear pharmacokinetic and pharmacodynamic profiles. Phase II and III clinical trials have been completed to examine its efficacy and safety in patients undergoing major orthopedic surgery. In these clinical trials, oral administration of edoxaban showed efficacy superior to that of oral placebo or subcutaneously administered dalteparin or enoxaparin. Edoxaban can be regarded as a first choice to prevent venous thromboembolism after major orthopedic surgery.
No takes yet. Share an insight, caveat, or question.
Kawaji et al. (2012) conducted a review in Venous thromboembolism after major orthopedic surgery. Edoxaban vs. Oral placebo, subcutaneous dalteparin, or subcutaneous enoxaparin was evaluated on Venous thromboembolism. Oral edoxaban showed superior efficacy to oral placebo or subcutaneous dalteparin or enoxaparin for preventing venous thromboembolism after major orthopedic surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: